Panacea Biotec's DengiAll Enters Phase III Trials

Panacea Biotec, an Indian pharmaceutical company, has initiated final Phase III trials for its single-dose dengue vaccine candidate, DengiAll. This vaccine, which has been under development for nearly 15 years, aims to combat the global surge in dengue infections, which affects almost half the world's population. Over 10,000 volunteers in India are participating in the trials, overseen by the India===Indian Council of Medical Research. If successful, DengiAll could be rolled out as early as next year, becoming the first single-dose dengue vaccine available in India and potentially the second globally after Brazil's recent approval of a similar shot. The vaccine is based on a tetravalent strain originally developed by the US United States===National Institutes of Health. Experts emphasize the critical need for such a vaccine in India, where dengue is hyperendemic, and highlight the potential for an affordable, Indian-made vaccine to facilitate mass rollout in lower-income countries. Final approval in India would come from the India===Drugs Controller General of India, with World Health Organization prequalification needed for international use.